糖链抗原19—9放免测定对诊断胃肠道潜隐癌的价值

对胃肠道潜隐癌、癌前病变和类性病变各３０例患者术前的糖链抗原１９－９水平进行回顾性分析，发现３组之间或两两比较均有明显差异。发现＜３７ｕ／ｍｌ者９７．４４％为良性病变，＞９０ｕ／ｍｌ者９４．４４％为恶性病变。３７－９０ｕ／ｍｌ之间者复查前后对比，癌变组血清ＣＡ１９－９水平平均升高１４．４２ｕ／ｍｌ，良性病变组平均下降９．６２ｕ／ｍｌ。提示对经内镜活组织检查未被证实的可疑胃肠道肿瘤患者，常规ＣＡ１９     

糖抗原CA19—9测定对消化系统恶性肿瘤的诊断意义

Serum carbohydrate antigen CA 19-9 level was measured by radioimmunoassay in 55 patients with malignant digestive disease (14 esophageal cancers, 11 gastric cancers, 5 colorectal cancers, 14 primary liver cancers and 11 pancreatic cancers). The mean value of serum CA 19-9 levels was 22.11 +/- 24.79 u/ml in esophageal cancer, 99.91 +/- 100.12 u/ml in gastric cancer, 64.5 +/- 53.43 u/ml in colorectal carcinoma, 47.81 +/- 68.62 u/ml in primary hepatic cancer and 459.55 +/- 696.76 u/ml in pancreatic cancer (CA 19-9 greater than 37 mu/ml as positive). There were significant differences (P less than 0.05) between the mean serum CA 19-9 levels of pancreatic cancer and esophageal cancer, primary hepatic cancer. An increased CA 19-9 synthesis and excretion by tumor cells or increased pressure on pancreatic duct by the tumor may cause the elevation of serum CA 19-9 level in cancer patients. The authors conclude that CA19-9 is a valuable tumor marker in the diagnosis of pancreatic cancer and, probably, other gastrointestinal tumors.     

CEA,CA19—9,CA50联合检测对胃肠道肿瘤的诊断价值

采用放射免疫法检测４１例胃肠恶性肿瘤和２０名健康人血清癌胚抗原（ＣＥＡ），糖链抗原（ＣＡ１９－９、ＣＡ５０）含量，并与癌组织学分类、有无淋巴结转移对比分析。结果显示：胃肠肿瘤ＣＥＡ、ＣＡ１９－９、ＣＡ５０值明显高于对照组（Ｐ〈０．０１）。胃癌伴肝、胰转移时ＣＡ１９－９增高尤其显著，胃癌ＣＡ５０值高于大肠癌（Ｐ〈０．０５）。胃肠肿瘤淋巴结转移者三项指标检出率较无转移者高，但差异无显著性。病理分类中胃     

血清CA_19－9测定对肺癌的诊断价值

检测５１例肺癌血清ＣＡ１９－９结果表明，肺癌组与正常组、肺良性疾病组比较，其检测值有非常显著差异（Ｐ＜０．０１），肺良性疾病组与正常组比较亦差异显著（Ｐ＜０．０５）。血清ＣＡ１９－９检测肺癌的敏感性为５０．９％，特异性为９０．９％，准确性为６９．５％。上述结果说明血清ＣＡ１９－９测定对提高肺癌的阳性检出率有重要的临床价值。     

血清CA19—9测定对肺癌的诊断价值

检测５１例肺癌血清ＣＡ１９－９。结果表明，肺癌组与正常组、肺良性疾病组比较，其检测值有非常显著差异（Ｐ〈０．０１），肺良性疾病组与正常组比较亦差异显著（Ｐ〈０．０５）。血清ＣＡ１９－９检测肺癌的敏感性为５０．９％，特异性为９０．９％，准确性为６９．５％。上述结果说明血清ＣＡ１９－９测定对提高肺癌的阳性检出率有重要的临床价值。     

联合检测CA19—9等六项标志物对肝胰癌的诊断价值

1991年4月至1998年5月,笔者对明确诊断的肝、胰腺癌患者98例和健康成年人30例联合进行血清肿瘤标志物CA19-9,CA50,AFP,CEA,SF及β_2M6项指标放射免疫法测定,以探讨其早期诊断肝、胰癌的临床价值.现报告如下:1 资料与方法1.1 研究对象1.1.1 肿瘤组 原发性肝癌(以下简称肝癌)72例中,男63例,女9例;年龄22岁～74岁,平均51岁,其中56例经手术及组织学病理诊断证实,15例不能切除的肝癌经临床和B超,CT、MRI及DSA两项以上影像诊断.胰腺癌26例中,男19例,女7例;年龄42岁～68岁,平均61例.均经手术及组织学病理诊断证实.1.1.2 对照组 为健康成年30例,肝功能和肝、     

CA_（19－9）和CA_（50）对消化道肿瘤的诊断价值

本文作者分别检测了１０６例消化道良性疾病患者及７８例癌肿患者血清ＣＡ１９－９和ＣＡ５０的含量，分析了肝脏、胰腺、胃及结直肠４组良，恶性疾病患者血清含量的变化及其临床意义。结果１０６例良性疾病ＣＡ１９－９和ＣＡ５０的上限值分别为３４ｕ／ｍｌ和１４ｕ／ｍｌ（ｘ±２Ｓ），其诊断的敏感性和特异性如下：ＣＡ１９－９对原发性肝癌分别为７５．０％和８６．９％，对胰腺癌分别为９１．７％和１００％，对胃癌分别为５５．６％和１００％；ＣＡ５０对原发性肝癌分别为５５．０％和７８．３％，对胰腺癌分别为９１．７％和１００％，对胃癌分别为５５．６％和１００％。ＣＡ１９－９与ＣＡ５０有高中度相关性，肝癌ｒ＝０．６２、胰腺癌ｒ＝０．６７、胃癌ｒ＝０；９０，Ｐ值均＜０．０１。因此认为ＣＡ１９－９和ＣＡ５０对消化道良、恶性疾病的诊断、鉴别有较高的临床价值，并对消化道癌肿有否转移及胃癌根治术是否彻底、术后有否复发的判断均具有一定临床意义。     

糖类抗原CA72—4、CA50、CA19—9联合检测对胃癌的诊断价值

近 30年来 ,胃癌的发病率及死亡率虽在世界范围内呈持续下降趋势 ,但仍是迄今死亡率最高的肿瘤之一[1] 。众所周知 ,目前的胃癌标志物在胃癌组织中检测的阳性率为 2 0 %～ 6 9%。我们联合检测了 6 9例胃癌、5 7例胃良性疾病患者及 40名正常人血清中ＣＡ 5 0、ＣＡ72 4及ＣＡ 19 9水平 ,以期为胃癌的早期诊断及治疗提供依据。1　材料和方法1.1　对象正常对照组 :40例 ,男性 2 7例 ,女性 13例 ,年龄 46～ 78岁 ,平均 ( 6 1.0± 17.2 )岁 ,均为我院体检合格者 ,无癌症、遗传性疾病家族史。胃癌组 :6 9例 ,男性 38例 ,女性 31例 ,年龄 42～ 76…     

Comparison of Serum Assays for TAG-72, CA19-9 and CEA in Gastrointestinal Carcinoma Patients

Tumor-associated glycoprotein (TAG-72) has been shown to beexpressed in a wide variety of epithelial malignant tissues.We have investigated serum levles of TAG-72 antigen in patientswith gastrointestinal cancer with a solid phase radioimmunometricassay (RIA), CA72-4, utiliz ing murine monoclonal antibodiesCC49 and B72.3 which recognize the TAG-72 antigen. Elevatedlevels of serum TAG-72 antigen were found in 48% of 56 gastriccarcinoma patients and 67% of 45 colorectal carcinoma patients.The serum concentrations of TAG-72 were compared to those ofCA19-9 and CEA. The positive rates of CA19-9 in gastric carcinomaand colorectal carcinoma patients were 29% and 54%, and thoseof CEA were 52% and 60%, respectively. Elevated serum levelsof TAG-72, CA19-9 and CEA were observed in 7%, 14% and 24%,respectively, of patients with benign disease, thus indicatinga preferential expression of TAG-72, compared to CA19-9 andCEA, in gastrointestinal carcinoma patients versus in patientswith benign disorder. A cocktail of CA72-4, CA19-9 and CEA RIAsincreased positive rates to 68% in sera of gastric cancer patientsand 84% in sera of colorectal cancer patients. Combination assays using CA72-4, CEA and CA19-9 RIM for patients with benigngastrointestinal disorder, however, also increased the positiverate to 31%. These results indicate that CA72-4, CA19-9 andCEA RIA may be complementary in detecting circulating tumor-associatedantigens. It must be emphasized, however, that interpretationof the data provided by the combination serum as says requirescareful consideration.     

Serum Carbohydrate Antigen 19-9 as an Indicator of LiverMetastasis in Colorectal Carcinoma Cases

Purpose: The liver is the organ to which colorectal carcinomas (CRCs) most commonly metastasize, andsurgical resection has been established as the most effective and potentially curative treatment for CRC withliver metastasis (LM). Therefore, surveillance of LM is vital for improvement of prognosis of CRC patients. Inthis study, we aimed to explore the potential value of carbohydrate antigen 19-9 (CA 19-9), carcinoembryonicantigen (CEA), and marker enzymes in indicating LM with CRC. Methods: Three groups of eligible patientswith metastatic cancers were retrospectively included: CRC patients with LM (CRC-LM) or without LM (CRCNLM),and non-CRC patients with LM (NCRC-LM). All metastatic lesions were identified by CT or MRI. Dataon characteristics of the patients, the primary site, the locations of metastasis, CA 19-9, CEA, and biochemicalparameters were collected for analysis. Results: A total of 493 patients were retrospectively included. Morealcohol consumption was found in CRC-LM than CRC-NLM. Some biochemical enzymes were found to besignificantly higher in groups with LM than without (CRC-LM or NCRC-LM v.s CRC-NLM). Both CEA andCA 19-9 were much higher in CRC-LM than CRC-NLM or NCRC-LM. For CRC patients, CA 19-9, γ-glutamyltranspeptidase, CEA and alcohol consumption were identified as independent factors associated with LM.Conclusion: Our analysis suggested the CA 19-9 might be a potential valuable indicator for LM of CRC in theclinic.     

大肠癌术后腹腔引流液中CEA、CA125和CA19-9的水平及其临床意义

目的 探讨大肠癌术后腹腔引流液中癌胚抗原（CEA）、糖类抗原125（CA125）和糖类抗原19-9（CA19-9）的水平及其与临床分期和腹腔微转移的关系。方法 收集经手术治疗的86例大肠癌患者（大肠癌组）和30例肠道良性疾病患者（对照组）术后第1天的腹腔引流液,检测腹腔引流液中CEA、CA125和CA19-9的水平,并分析其与大肠癌临床病理特征的关系。结果 大肠癌组腹腔引流液的CEA水平高于对照组（P＜0.05）,CA125和CA19-9水平两组差异均无统计学意义（P＞0.05）;腹腔引流液中CA125和CA19 9水平与大肠癌临床病理特征无关（P＞0.05）,而CEA水平与淋巴结转移、浸润深度和临床分期有关。结论 大肠癌术后腹腔引流液CEA检测可用于预测临床分期、腹腔微转移并判断预后。     

血清肿瘤标志物CEA、CA19-9对结直肠癌的诊断价值

目的 分析血清肿瘤标志物CEA、CA19-9单项或联合检测对结直肠癌患者的临床诊断价值,探讨其在病理分期、淋巴结转移等临床特征方面的意义.方法 酶联免疫法检测160例健康人和158例结直肠癌患者术前两天以及术后两周血清中CEA、CA19-9含量.结果 结直肠癌患者2种血清肿瘤标志物含量明显高于健康人(P<0.01),术前与术后2种血清肿瘤标志物水平比较差异有统计学意义(P<0.05).CEA、CA19-9联合检测敏感度和特异度明显高于各单项检测值.在Dukes A、B、C及D期中,2种肿瘤标志物含量及检测阳性率依次增高,淋巴结转移患者的CA19-9含量高于无淋巴结转移患者(P<0.05).结论 肿瘤标志物CEA、CA19-9联合检测可以提高结直肠癌诊断的敏感度和特异度,并对临床分期、判断淋巴结转移、预测预后及监测复发有一定的指导意义.     

消化道恶性肿瘤TSGF、CA19-9、CA242联合检测的临床评价

目的　探讨用恶性肿瘤特异性生长因子 (TSGF)、糖抗原 19 9(CA19 9)与糖抗原 2 42 (CA2 42 )联合检测对消化道恶性肿瘤的临床评价。方法　采用酶免疫测定 140例消化道肿瘤及 30例正常人血清。结果　以单一指标阳性作为诊断标准CA2 42、CA19 9、TSGF对消化道恶性肿瘤的灵敏度分别为 42 9%、5 5 7%、80 7% ,准确度分别为 5 2 9%、6 2 4%、81 8% ,联合检测结果二项或二项以上阳性作为标准则本组患者的诊断的灵敏度为 84 3% ,准确度为 87 6 %。结论　联合检测血清TSGF、CA19 9与CA2 42对消化道恶性肿瘤的辅助诊断有较高的临床应用价值。     

血清CA19—9的酶免测定及临床应用

本文用生物素—链霉亲和素酶联免疫吸附试验（BSA）对203例血清CA19－9水平进行定量测定。结果显示，在32例胰腺癌组为826±411U／ml，40例肝癌组为107±46．5U／ml，与76例正常人对照组21．2±9．24U／ml比较均有明显差异（P＜0．05），以胰腺癌组升高最显著。在39例胃癌组为25．4±11．0U／ml，与正常对照组比较均无明显差异（P＞0．05）。27例胰腺癌病人术前为910±452U／ml，术后为187±89．0U／ml，血清CA19－9水平明显下降（P＜0．05）。血清CA19－9水平分析对胰腺癌的鉴别诊断、疗效观察及预后评估有较高价值。     

Diagnostic value of preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 in colorectal cancer

Background

Since the first introduction of tumour markers, their usefulness for diagnosis has been a challenging question. The aim of the present prospective study was to investigate, in colorectal cancer patients, the relationship between preoperative tumour marker concentrations and various clinical variables.

Methods

The study prospectively enrolled 131 consecutive patients with a confirmed diagnosis of colorectal carcinoma and 131 age- and sex-matched control subjects with no malignancy. The relationships of the tumour markers carcinoembryonic antigen (cea) and carbohydrate antigen (ca) 19-9 with disease stage, tumour differentiation (grade), mucus production, liver function tests, T stage, N stage, M stage were investigated.

Results

Serum concentrations of cea were significantly higher in the patient group than in the control group (p = 0.001); they were also significantly higher in stage iii (p = 0.018) and iv disease (p = 0.001) than in stage i. Serum concentrations of cea were significantly elevated in the presence of spread to lymph nodes (p = 0.005) in the patient group. Levels of both tumour markers were significantly elevated in the presence of distant metastasis in the patient group (p = 0.005 for cea; p = 0.004 for ca 19-9).

Conclusions

Preoperative levels of cea and ca 19-9 might provide an estimate of lymph node invasion and distant metastasis in colorectal cancer patients.     

血清CEA、CA19—9、CA724检测对老年胃癌病理、临床分期的意义

目的：探讨血清CEA、CA19—9、CA724对老年胃癌的临床应用价值。方法：采用ELISA方法对87例老年胃癌患者进行回顾性分析。结果：老年胃癌患者CEA、CA19—9、CA724阳性率分别为25％、21％、21％,联合检测阳性率为41％,其中TNMIV期患者CA19—9、CA724、联合检测阳性率明显高于TNMⅠ＋Ⅱ期患者。TNMⅢ＋Ⅳ期患者CA19—9、CA724检测值明显高于Ⅰ＋Ⅱ期患者。CEA、CA19—9、CA724阳性率、其值大小与胃癌病理类型、分化无关。结论：CEA、CA19—9、CA724可用于老年胃癌的诊断、病情判断,联合检测可提高诊断效率,但早期诊断价值有限。